Presented by Prof Dr Eric Van Cutsem & Prof Dr Jeroen Dekervel (University Hospitals, Leuven, Belgium)
At ASCO 2025, a highlight in gastric cancer was the presentation of the DESTINY-Gastric04 trial, a pivotal phase 3 study evaluating T-DXd versus the current standard of care, ramucirumab plus paclitaxel, in patients with previously treated HER2-positive advanced gastric or gastroesophageal junction cancer. About 15% of gastric cancers are HER2-positive, and while trastuzumab has long been established as first-line therapy since the TOGA trial, effective options beyond first line have remained limited. T-DXd, already approved in later lines based on DESTINY-Gastric02, was here tested head-to-head against the second-line standard.
The trial required reconfirmation of HER2 positivity via biopsy before randomisation. Patients received either T-DXd every three weeks or standard ramucirumab-paclitaxel. The primary endpoint was OS, with the study meeting its objective: T-DXd significantly prolonged OS by 3.3 months compared to standard treatment. Secondary endpoints, including PFS and ORR also favoured T-DXd, with an ORR of 44% — notably high in this setting. However, the duration of response, while superior to standard care, was more modest than what has been observed in other tumour types like breast cancer, reflecting the intrinsic biological resistance of gastric cancer.
Safety outcomes were consistent with previous experience. The higher T-DXd dose used in gastric cancer compared to breast cancer was generally tolerable, with ILD occurring in 13% of patients, predominantly grade 1–2 events, likely mitigated by increased clinician vigilance and early intervention. Other adverse effects aligned with the known profile of deruxtecan’s irinotecan-derived payload, manageable within standard GI oncology practice.
An important clinical consideration discussed by Prof Van Cutsem and prof Jeroen De Kervel involved the necessity of re-biopsy before second-line T-DXd, as mandated in the trial but not required by the EMA label. Given HER2 heterogeneity and the practical challenges of repeat biopsies, both experts advocated for a pragmatic approach: perform a biopsy when feasible and clinically justified, but accept treatment without one if logistics or patient factors make it difficult.
Looking ahead, T-DXd’s role in first-line therapy is under exploration in ongoing trials combining it with other agents, though results are not expected before ASCO 2028. For now, T-DXd firmly establishes itself as a new second-line standard for HER2-positive gastric cancer, offering a meaningful survival benefit and manageable safety profile in a disease setting historically lacking effective post-progression options.
Reference:
Shitara K. et al., ASCO 2025, LBA4002
Donderdag 12 november 2026
Kontich
Gent
Linter
Onthaal vanaf 18 uur
Programma van 19 tot 22 uur
Kies jouw locatie en schrijf je in
Donderdag 12 november 2026
Kontich
Gent
Linter
Onthaal vanaf 18 uur
Programma van 19 tot 22 uur
Kies jouw locatie en schrijf je in